

Puravankara (PL)'s pre-sales growth of 4% YoY to Rs13.2bn (in-line) in Q2FY26 largely came from sustenance sales; Thane projects provided growth delta as the West reported 150% YoY growth, albeit on a low base. Planned launch pipeline remains largely on track, and would open up Rs100-120bn inventory in H2FY26 which would, along with sustenance sales, drive a strong 36% pre-sales CAGR during FY25-27E. The company has made strong progress on the business development (BD) front, adding Rs91bn GDV in H1FY26. Also, these being asset-light projects keep leverage under check vis-à-vis improving the growth visibility. More deals are expected ahead which would lead to growth continuity in the medium term. We maintain BUY on the stock with TP of Rs400.

In-line pre-sales; Thane project provides growth delta

PL's Q2FY26 pre-sales grew 4% YoY to Rs13.2bn (in-line), which is resilient, as the performance is largely on the back of sustenance sales. The growth was supported by the Thane project, which propelled 150% YoY growth in western-region sales to Rs3.6bn. Sales in the South declined 15% YoY to Rs9.6bn, due to no new launches during the quarter. Consequently, the share of Mumbai and Pune in the value mix increased to 25% in H1FY26 (vs 15% in FY25). Collections grew 8% YoY to Rs10.5bn in Q2FY26.

Impressive progress on asset-light project additions, with focus on the West

PL made strong progress on the BD front as it acquired four projects that offer Rs91bn GDV potential. Of these, two projects with Rs48bn GDV were added in Mumbai (one redevelopment project each, in Malabar Hill and Chembur). The other two projects with Rs43bn GDV were in Bengaluru on JV/JDA basis. We expect more deal closures in Mumbai and Pune in coming quarters; this would provide even better geographic diversification with higher focus on the West. Further, as these BD projects have been via the asset-light route, they would keep growth intact vis-à-vis leverage under check.

Launch pipeline remains healthy

The company's launch for H2FY26 pipeline, worth Rs120bn, largely remains on track. It includes the much-awaited launches in Mumbai, wherein approvals for the Andheri project are largely received; approvals for the Thane new phase and Bandra projects are expected by Dec-end. We maintain pre-sales estimates of Rs71bn/Rs93bn for FY26E/27E, respectively. Further, with progress in construction activity and inflows from new pre-sales, we expect collections at Rs46bn/Rs63bn in FY26E/FY27E, respectively.

We maintain BUY

We value the residential business at 6x embedded EV/EBITDA (EV of Rs106bn) and commercial business on 8.5% cap-rate (EV of Rs22bn). At net debt of Rs35bn (on Mar-26E), we keep our SoTP-based target price unchanged at Rs400 and maintain BUY on the stock. At CMP, the stock is trading at 30% discount to the residential business NAV.

Target Price – 12M	Mar-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	57.5

Stock Data	PURVA IN
52-week High (Rs)	464
52-week Low (Rs)	205
Shares outstanding (mn)	237.1
Market-cap (Rs bn)	60
Market-cap (USD mn)	679
Net-debt, FY26E (Rs mn)	35,261.5
ADTV-3M (mn shares)	0
ADTV-3M (Rs mn)	64.9
ADTV-3M (USD mn)	0.7
Free float (%)	25.0
Nifty-50	25,574.3
INR/USD	88.7

Shareholding, Sep-25

Promoters (%)	75.0
FPIs/MFs (%)	17.2/0.5

Price Performance

(%)	1M	3M	12M
Absolute	1.5	(4.8)	(39.8)
Rel. to Nifty	0.4	(9.3)	(43.1)

1-Year share price trend (Rs)



Puravankara: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	21,853	20,136	32,866	36,313	40,366
EBITDA	4,628	2,909	7,476	8,496	9,720
Adj. PAT	423	(1,806)	1,521	2,308	3,295
Adj. EPS (Rs)	1.8	(7.6)	6.4	9.7	13.9
EBITDA margin (%)	21.2	14.4	22.7	23.4	24.1
EBITDA growth (%)	101.5	(37.1)	157.0	13.6	14.4
Adj. EPS growth (%)	(36.4)	0	0	51.7	42.8
RoE (%)	2.2	(10.0)	8.6	12.3	16.0
RoIC (%)	6.9	5.0	9.1	10.2	11.7
P/E (x)	142.5	(33.2)	39.6	26.1	18.3
EV/EBITDA (x)	18.1	28.8	11.2	9.9	8.6
P/B (x)	3.2	3.5	3.3	3.1	2.8
FCFF yield (%)	5.9	(5.6)	4.4	1.8	10.4

Source: Company, Emkay Research

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/11/2025.

Harsh Pathak

harsh.pathak@emkayglobal.com
+91-22-66121344


Harsh Shah

harsh.shah@emkayglobal.com
+91-22-66242468

Q2FY26 operational performance


- Puravankara clocked Rs13.2bn pre-sales (+4% YoY) during Q2FY26 – broadly in line with our expectations. While the YoY growth looks sluggish, this has largely been from sustenance sales – which is a positive.
- In H1FY26, pre-sales grew 4% YoY to Rs24.5bn.
- Collections grew 8% YoY to Rs10.5bn in Q2FY26.
- In H1FY26, the company acquired four new projects (all asset-light) offering GDV potential of Rs91bn, which improves the medium-term growth visibility.

Exhibit 1: Quarterly pre-sales trend



Source: Company, Emkay Research

Exhibit 2: Quarterly collections trend



Source: Company, Emkay Research

Exhibit 3: Sales based on bookings

	Q1FY25	Q2FY25	Q1FY26	Q2FY26
Purva South				
Completed projects				
-Area sold (msf)	0.1	0.1	0.2	0.2
-Units sold (no of)	91	45	129	150
-Sales value (Rs bn)	1.0	0.5	1.5	1.8
-Sale realization (Rs)	8,927	9,034	9,237	9,877
Ongoing projects				
-Area sold (msf)	1.0	1.4	0.8	0.9
-Units sold (no of)	840	1,077	594	720
-Sales value (Rs bn)	7.9	10.8	7.0	7.8
-Sale realization (Rs)	7,856	8,014	8,905	8,505
West and Commercial				
Completed projects				
-Area sold (msf)	0.01	0.01	0.01	-
-Units sold (no of)	12	8	12	-
-Sales value (Rs bn)	0.1	0.1	0.1	-
-Sale realization (Rs)	12,060	6,780	11,550	-
Ongoing projects				
-Area sold (msf)	0.2	0.1	0.3	0.4
-Units sold (no of)	163	129	260	381
-Sales value (Rs bn)	1.6	1.4	2.6	3.6
-Sale realization (Rs)	10,002	10,507	8,990	9,035

Source: Company, Emkay Research

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) user and downloaded at 11/11/2023 11:55:45 AM.

Business development with focus on the West

Puravankara acquired four projects in H1FY26 which offer a GDV potential of Rs91bn. These include two redevelopment projects in Mumbai (one each in Chembur and Malabar Hill) and two JV/JDA projects in Bengaluru. As these have been through the asset-light route, despite sizable additions, balance sheet strength would remain under check vis-à-vis improve growth visibility, with better diversification (growing its presence in the West).

New projects added in H1FY26:

- **Chembur (Mumbai) redevelopment:** Selected as the preferred developer for 8 residential societies, offering a GDV potential of Rs21bn.
- **Malabar Hill (Mumbai) redevelopment:** Project has ~0.7msf developable area offering GDV of Rs27bn.
- **North Bengaluru (JV):** Partnered with KVN Property Holdings for ~3.5msf developable area, offering GDV potential of Rs33bn. Launch targeted in the next 4-6 months.
- **East Bengaluru (JD):** Project has ~0.85msf developable area offering Rs10bn GDV. Launch expected in the next 6-9 months.

Exhibit 4: Launches planned

Project/ Location	City	Development model	Developable area (msf)	Group's share in JD (%)	Saleable area (msf)	Inventory to be opened at the time of launch (msf)	Expected launch
Puravankara South							
Bellandur	Bengaluru	Owned	0.5	100%	0.5	0.5	Q4FY26
Puravankara- Winworth - 2	Kochi	Owned	1.3	100%	1.3	0.6	Q4FY26
Grand Hills	Bengaluru	Owned	0.8	100%	0.8	0.8	Q4FY26
Hebbagodi	Bengaluru	Owned	0.8	100%	0.8	0.8	Q3FY26
Westend	Bengaluru	JDA	0.3	65%	0.3	0.3	Q4FY26
Hennur Road	Bengaluru	Owned	0.4	100%	0.4	0.4	Q4FY26
Cityspire - Winworth - 2	Kochi	Owned	1.7	100%	1.7	0.4	Q4FY26
Mallasandra	Bengaluru	Owned	0.8	100%	0.8	0.4	Q3FY26
Kanakpura	Bengaluru	Owned	0.5	100%	0.5	0.5	Q4FY26
KIADB	Bengaluru	Owned	3.5	67%	3.5	1.2	Q4FY26
Nellakunte (plotted)	Bengaluru	Owned	0.2	100%	0.2	0.2	Q3FY26
Total			10.7		10.7	6.1	
Puravankara West							
Apna ghar redevelopment (Units 4&5) Mumbai	Mumbai	Redevelopment	1.1	100%	0.6	0.3	Q4FY26
Miami	Mumbai	Redevelopment	0.2	100%	0.1	0.0	Q1FY27
Deccan	Mumbai	Redevelopment	0.7	100%	0.4	0.1	Q4FY26
Total			1.9		1.1	0.4	
Grand total - New launches							
New phase launches							
Total launches							

Source: Company, Emkay Research

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/

Exhibit 5: Puravankara expands its redevelopment portfolio in Mumbai



Acres – 4.97
Saleable Area - 0.63 msft (Unit 4 & 5)
Location – Apnagar, Lokhandwala, Mumbai
DA signed for unit 4 & 5.
DA is in process for Unit 3 - 0.27 msft

Acres – 2.6
Saleable Area – 0.36 msft
Location – Deccan, Pali Hills, Mumbai
Development agreement signed.

Acres – 0.60
Saleable Area – 0.08 msft
Location – Miami, Breach Candy, Mumbai
Development agreement signed.

Acres – 3.78
Saleable Area – 0.98 msft
Location – Deonar Baug, Chembur, Mumbai
Appointed as preferred developer. MOU signed, DA is underway.

Acres – 1.43
Saleable Area – 0.35 msft
Location – Malabar Hills, Mumbai
Appointed as preferred developer. DA is under process

Source: Company

Exhibit 6: Direct cashflows

(Rs bn)	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26
Collections from operations	8.9	10.7	11.2	9.7	11.8	106.2	11.3	9.6	11.8
Operating inflows (A)	8.9	10.7	11.2	9.7	11.8	106.2	11.3	9.6	11.8
Operating outflows (B)	-5.9	-6.5	-7.9	-6.9	-8.7	-89.8	-9.3	-8.1	-8.7
Operating Surplus (C=A-B)	3.0	4.2	3.3	2.8	3.1	1.6	2.0	1.5	3.1
Less									
Interest cost (Net)	-0.9	-0.8	-2.0	-1.0	-1.2	-1.3	-1.3	-1.2	-1.8
Tax paid	-0.4	-0.4	-0.5	-0.3	-0.5	-0.4	-0.6	-0.7	-0.5
Operating Surplus after tax and interest (D)	1.8	3.0	0.8	1.4	1.4	-0.1	0.1	-0.3	0.8
Land payments, including advances & deposits	-0.1	-0.2	-0.7	-6.3	-3.2	-2.9	-0.5	-1.4	-0.3
Purchase of Fixed Assets	-0.2	0.0	0.0	0.0	0.0	0.0	-0.3	-0.1	-0.2
Other Assets and Investments	-0.8	-0.3	0.0	0.0	0.0	-0.4	-0.5	-0.1	0.0
Total from Investing Activities (E)	-1.1	-0.5	-0.7	-6.3	-3.2	-3.3	-1.2	-1.7	-0.5
Loan drawal/(Repayments)	0.4	-0.5	5.2	2.0	0.9	1.4	1.2	-1.4	0.6
Exit/Investment equity in nature	0.7	0.1	-2.8	4.0	-0.2	0.0	-0.1	3.2	-1.0
Loan to associates/subsidiaries/others - inflow/(outflow)	-0.1	0.0	0.1						
Dividend (net of TDS)		0.0	-1.5						
Total from Financing Activity (F)	0.9	-0.5	1.0	6.0	0.7	1.4	1.1	1.8	-0.4
Net Operating surplus (G=D+E+F)	1.6	2.0	1.1	1.1	-1.1	-2.0	0.0	-0.1	-0.1
Opening Cash and Bank Balances	4.6	6.2	8.2	9.3	10.4	9.4	7.4	7.3	7.2
Closing Cash and Bank Balances	6.2	8.2	9.3	10.4	9.4	7.4	7.3	7.2	7.1

Source: Company, Emkay Research

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/

Exhibit 7: Debt composition

(Rs bn)	FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26
Residential	23.6	22.9	21.9	21.9	20.6	18.9	19.2
Land	5.2	7.5	8.8	8.9	10.5	10.4	10.1
Capex towards commercial development	2.0	2.4	3.0	4.8	5.7	6.1	6.6
Total Gross debt**	30.8	32.8	33.7	35.6	36.8	35.4	36.0
Less: Cash and Cash equivalents	9.3	10.4	9.4	7.4	7.3	7.2	7.1
Net debt	21.5	22.4	24.3	28.2	29.5	28.3	28.9

Source: Company, Emkay Research; ** debt does not include NCD issued to HCARE fund 3 of Rs6.1bn, Rs500mn of 360 One and Purva Excellence fund of Rs1.2bn as these investments are when "payable when able" nature ; ~Rs970mn unamortised processing fee, accrued interest and others

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/11/2023 11:11:11 AM

Puravankara: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	21,853	20,136	32,866	36,313	40,366
Revenue growth (%)	76.8	(7.9)	63.2	10.5	11.2
EBITDA	4,628	2,909	7,476	8,496	9,720
EBITDA growth (%)	101.5	(37.1)	157.0	13.6	14.4
Depreciation & Amortization	281	350	489	571	675
EBIT	4,348	2,560	6,987	7,925	9,045
EBIT growth (%)	104.5	(41.1)	173.0	13.4	14.1
Other operating income	487	493	521	551	583
Other income	748	795	788	816	847
Financial expense	4,342	5,548	5,514	5,271	4,902
PBT	754	(2,193)	2,261	3,471	4,989
Extraordinary items	0	(8)	0	0	0
Taxes	262	(294)	791	1,215	1,746
Minority interest	3	30	2	2	2
Income from JV/Associates	(72)	62	50	50	50
Reported PAT	423	(1,814)	1,521	2,308	3,295
PAT growth (%)	(36.4)	0	0	51.7	42.8
Adjusted PAT	423	(1,806)	1,521	2,308	3,295
Diluted EPS (Rs)	1.8	(7.6)	6.4	9.7	13.9
Diluted EPS growth (%)	(36.4)	0	0	51.7	42.8
DPS (Rs)	6.3	0	3.0	4.0	4.0
Dividend payout (%)	353.6	0	46.8	41.1	29.1
EBITDA margin (%)	21.2	14.4	22.7	23.4	24.1
EBIT margin (%)	19.9	12.7	21.3	21.8	22.4
Effective tax rate (%)	34.8	13.4	35.0	35.0	35.0
NOPLAT (pre-IndAS)	2,834	2,216	4,542	5,151	5,879
Shares outstanding (mn)	237	237	237	237	237

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	(66)	(2,926)	1,523	2,705	4,192
Others (non-cash items)	281	823	(148)	(148)	(148)
Taxes paid	(683)	(322)	(791)	(1,215)	(1,746)
Change in NWC	6,222	(11,506)	9,382	6,320	7,686
Operating cash flow	8,964	(5,307)	13,958	9,781	15,179
Capital expenditure	(3,998)	630	(10,281)	(8,273)	(6,435)
Acquisition of business	685	(42)	(12)	(12)	(13)
Interest & dividend income	389	252	788	816	847
Investing cash flow	129	(736)	(7,348)	(3,601)	(5,071)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	3,587	10,111	(1,000)	(2,000)	(3,000)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(4,342)	(5,548)	(5,514)	(5,271)	(4,902)
Dividend paid (incl tax)	(1,494)	0	(711)	(949)	(958)
Others	(876)	(1,028)	3	4	4
Financing cash flow	(3,126)	3,535	(7,222)	(8,216)	(8,857)
Net chg in Cash	5,967	(2,509)	(612)	(2,035)	1,251
OCF	8,964	(5,307)	13,958	9,781	15,179
Adj. OCF (w/o NWC chg.)	2,742	6,198	4,576	3,462	7,492
FCFF	4,966	(4,678)	3,677	1,508	8,744
FCFE	1,012	(9,974)	(1,049)	(2,946)	4,689
OCF/EBITDA (%)	193.7	(182.4)	186.7	115.1	156.2
FCFE/PAT (%)	239.6	549.9	(69.0)	(127.7)	142.3
FCFF/NOPLAT (%)	175.2	(211.1)	81.0	29.3	148.7

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	1,186	1,186	1,186	1,186	1,186
Reserves & Surplus	17,646	16,123	16,935	18,297	20,636
Net worth	18,831	17,309	18,121	19,482	21,821
Minority interests	64	50	48	46	44
Non-current liab. & prov.	(2,678)	(2,839)	(3,003)	(3,033)	(3,063)
Total debt	32,856	42,967	41,967	39,967	36,967
Total liabilities & equity	49,074	57,486	57,132	56,462	55,768
Net tangible fixed assets	1,554	2,287	10,053	14,032	19,406
Net intangible assets	74	30	35	40	45
Net ROU assets	-	-	-	-	-
Capital WIP	23	1	15	15	15
Goodwill	-	-	-	-	-
Investments [JV/Associates]	355	397	409	421	434
Cash & equivalents	9,311	7,317	6,705	4,670	5,921
Current assets (ex-cash)	94,067	121,887	135,193	157,777	184,604
Current Liab. & Prov.	65,516	81,992	104,844	133,778	168,322
NWC (ex-cash)	28,551	39,895	30,349	23,999	16,283
Total assets	49,074	57,486	57,132	56,462	55,768
Net debt	23,545	35,650	35,261	35,297	31,046
Capital employed	49,073	57,486	57,132	56,462	55,768
Invested capital	39,384	49,771	50,003	51,355	49,398
BVPS (Rs)	79.4	73.0	76.4	82.1	92.0
Net Debt/Equity (x)	1.3	2.1	1.9	1.8	1.4
Net Debt/EBITDA (x)	5.1	12.3	4.7	4.2	3.2
Interest coverage (x)	1.2	0.6	1.4	1.7	2.0
RoCE (%)	10.1	6.0	12.9	14.6	16.7

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	142.5	(33.2)	39.6	26.1	18.3
EV/CE(x)	1.6	1.4	1.4	1.4	1.4
P/B (x)	3.2	3.5	3.3	3.1	2.8
EV/Sales (x)	3.9	4.3	2.6	2.3	2.1
EV/EBITDA (x)	18.1	28.8	11.2	9.9	8.6
EV/EBIT(x)	19.3	32.7	12.0	10.6	9.3
EV/IC (x)	2.1	1.7	1.7	1.6	1.7
FCFF yield (%)	5.9	(5.6)	4.4	1.8	10.4
FCFE yield (%)	1.7	(16.6)	(1.7)	(4.9)	7.8
Dividend yield (%)	2.5	0	1.2	1.6	1.6
DuPont-RoE split					
Net profit margin (%)	1.9	(9.0)	4.6	6.4	8.2
Total asset turnover (x)	0.5	0.4	0.6	0.6	0.7
Assets/Equity (x)	2.5	2.9	3.2	3.0	2.7
RoE (%)	2.2	(10.0)	8.6	12.3	16.0
DuPont-RoIC					
NOPLAT margin (%)	13.0	11.0	13.8	14.2	14.6
IC turnover (x)	0.5	0.5	0.7	0.7	0.8
RoIC (%)	6.9	5.0	9.1	10.2	11.7
Operating metrics					
Core NWC days	476.9	723.2	337.0	241.2	147.2
Total NWC days	476.9	723.2	337.0	241.2	147.2
Fixed asset turnover	2.2	1.7	2.0	1.4	1.2
Opex-to-revenue (%)	31.4	40.9	30.5	30.9	30.8

Source: Company, Emkay Research


This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/11/2023.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
02-Sep-25	290	400	Buy	Harsh Pathak
10-Aug-25	267	400	Buy	Harsh Pathak
13-Jul-25	288	400	Buy	Harsh Pathak
10-Jul-25	291	400	Buy	Harsh Pathak
01-Jun-25	265	400	Buy	Harsh Pathak
11-May-25	218	400	Buy	Harsh Pathak
14-Feb-25	234	430	Buy	Harsh Pathak
26-Jan-25	277	430	Buy	Harsh Pathak

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/11/2025.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 11, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 11, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 11, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/11/2025.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Harsh Pathak (harsh.pathak@emkayglobal.com) use and downloaded at 11/11/2023 11:11:11 AM